Expression pattern of somatostatin receptor subtypes 1-5 in human skin: An immunohistochemical study of healthy subjects and patients with psoriasis or atopic dermatitis

Experimental Dermatology

Volumn 15, Issue 12, 2006, Pages 950-957

  Hagströmer, Lena ^a   Emtestam, Lennart ^a   Stridsberg, Mats ^b   Talme, Toomas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atopic dermatitis; Immunohisto chemistry; Neuropep tides; Psoriasis; Somatostatin receptors

Indexed keywords

SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DERMIS; EPIDERMIS; FEMALE; HAIR FOLLICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE CELL; NERVOUS SYSTEM; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSORIASIS; SEBACEOUS GLAND; SKELETAL MUSCLE; SKIN BIOPSY; STAINING; SWEAT GLAND; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PSORIASIS; RECEPTORS, SOMATOSTATIN; SKIN;

EID: 33750626838     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2006.00487.x     Document Type: Article

References (60)

1. Reichlin S. Somatostatin. N Engl J Med 1983: 309: 1495-1501, 1556-1563.
2. Patel Y C. General aspects of the biology and function of somatostatin. In: Weil C, Muller E E, Thorner M O, eds. Basic and Clinical Aspects of Neuroscience. Berlin: Springer-Verlag, 1992: 1-16.
3. Patel Y C. Somatostatin and its receptor family. Front Neuroendocrin 1999: 20: 157-198.
4. Johansson O, Nordlind K. Immunohistochemical localization of somatostatin-like immunoreactivity in skin lesions from patients with urticaria pigmentosa. Virchows Arch 1984: 46: 155-164.
5. Johansson O, Vaalasti A. Immunohistochemical evidence for the presence of somatostatin-containing sensory nerve fibres in the human skin. Neurosci Lett 1987: 73: 225-230.
6. Wollina U, Mahrle G. Epidermal Merkel cells in psoriatic lesions: immunohistochemical investigations on neuroendocrine antigen expression. J Dermatol Sci 1992: 3: 145-150.
7. Fantini F, Johansson O. Neurochemical markers in human cutaneous Merkel cells. An immunohistochemical investigation. Exp Dermatol 1995: 4: 365-371.
8. Johansson O, Hilliges M, Talme T, Marcusson J A, Wetterberg L. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment. Acta Derm Venereol 1994: 74: 106-109.
9. Raynor K, Reisine T. Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J Pharmacol Exp Ther 1989: 251: 510-517.
10. Rens-Domiano S, Law S F, Yamada Y, Seino S, Bell G I, Reisine T. Pharmacological properties of two cloned somatostatin receptors. Mol Pharmacol 1992: 42: 28-34.
11. Yasuda K, Rens-Domiano S, Breder C D et.al. Cloning of a novel somatostatin receptor SSTR3, coupled to adenylcyclase. J Biol Chem 1992: 267: 20422-20428.
12. Raynor K, Coy D C, Reisine T. Analogues of somatostatin bind selectively to brain somatostatin receptor subtypes. J Neurochem 1992: 59: 1241-1250.
13. Raynor K, O'Carrol A M, Kong H et.al. Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol Pharmacol 1993: 44: 385-392.
14. Hocart S J, Jain R, Murphy W A, Taylor J E, Morgan B, Coy D H. Potent antagonists of somatostatin: Synthesis and biology. J Med Chem 1998: 41: 1146-1154.
15. Brazeau P, Vale W W, Burgus R et.al. Hypothalamic peptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973: 179: 77-79.
16. Epelbaum J, Dornauad P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 1994: 153: 1180-1186.
17. Editorial. Octreotide steaming ahead. Lancet 1992: 339: 837-839.
18. Karalis K, Mastorakos G, Chrousos G P, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994: 93: 2000-2006.
19. Fioravanti A, Govoni M, La Montagna G et.al. Somatostatin 14 and joint inflammation: Evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exp Clin Res 1995: 21: 97-103.
20. Keri G Y, Érchegyi J, Horvath A et.al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci USA 1996: 93: 12513-12518.
21. Gianetti N, Enjalbert A, Krantic S. Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: Relevance of the adenyl cyclase stimulation. J Cell Biochem 2000: 78: 666-673.
22. O'Byrne K J, Dobbs N, Propper D J et.al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999: 79: 1413-1418.
23. Raderer M, Hejna M H, Muller C et.al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000: 16: 1197-1201.
24. Witzig T E, Letendre L, Gerstner J et.al. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: Results of a phase II North Central Cancer Treatment Group Trial. J Clin Oncol 1995: 13: 2012-2015.
25. Hanifin J M, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980: 92(Suppl.): 44-47.
26. Portela-Gomes G M, Stridsberg M, Grimelius L, Öberg K, Jansson E T. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morph 2000: 8: 126-132.
27. Ludvigsen E, Olsson R, Stridsberg M, Janson E T, Sandler S. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 2004: 52: 391-400.
28. O'Shaughnessy D J. Radioimmunoassay of gut regulatory peptides. In: Bloom S R, Long R D, eds. Antibodies. London: WB Saunders, 1982: 9-20.
29. Vaitukaitis J, Robbins J B, Nieschlag E, Ross G T. A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol 1971: 33: 988-991.
30. Fjällskog M-L, Ludvigsen E, Stridsberg M, Öberg K, Eriksson B, Jansson E T. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003: 20: 59-67.
31. Corleto V D, Severi C, Romano G I et.al. Somatostatin receptor subtypes mediate contractility on human colonic smooth muscle cells. Neurogastroenterol Motil 2006: 18: 217-225.
32. Georgii-Hemming P, Strömberg T, Janson E T, Stridsberg M, Jernberg Wiklund H, Nilsson K. The somatostatin analogue octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6 independent human multiple myeloma cell lines. Blood 1999: 93: 1724-1731.
33. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocrine Rev 2000: 21: 457-487.
34. Steinhoff M, Ständer S, Seeliger S, Ansel J, Scmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003: 139: 1479-1488.
35. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000: 80: 979-1020.
36. Slominski A, Wortsman J, Pisarchik A et.al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J 2001: 15: 1678-1693.
37. Pincelli C, Fantini F, Romualdi P et.al. Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of human cultured keratinocytes. J Invest Dermatol 1992: 98: 421-427.
38. Eedy D J. Neuropeptides in skin. Br J Dermatol 1993: 128: 597-605.
39. Raydchaudhuri S P, Farber E M. Neuropeptides and neurogenic inflammation. In: Roenigk H H, Maibach H, eds. Psoriasis, 3rd edn. New York: Marcel Dekker, Inc., 1998: 383-391.
40. Urashima R, Mihara M. Cutaneous nerves in atopic dermatitis. A histological, immunohistochemical and electron microscopic study. Virchows Arch 1998: 432: 363-370.
41. Farber E M, Nickoloff B J, Recht B, Fraki J. Stress, symmetry and psoriasis: Possible role of neuropeptides. J Am Acad Dermatol 1986: 14: 305-311.
42. Mallbris L, Larsson P, Bergqvist S, Vingård E, Granath F, Ståhle M. Psoriasis phenotype at disease onset: Clinical characterization of 400 adult cases. J Invest Dermatol 2005: 124: 499-504.
43. Pallanti S, Lotti T, Urpe M. Psychoneuroimmunodermatology of atopic dermatitis: From empiric data to the evolutionary hypothesis. Dermatol Clin 2005: 23: 695-701.
44. Farber E M, Lanigan S, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis. Int J Dermatol 1990: 29: 418-420.
45. Payan D G, Hess C A, Goetzl E J. Inhibition by somatostatin of the proliferation of T lymphocytes and molt-4 lymphoblasts. Cell Immunol 1984: 84: 433-438.
46. Blum A M, Metwali A, Mathew R C, Elliott D, Weinstock J V. Substance P and somatostatin can modulate the amount of IgG2a secreted in response to schistosome egg antigens in murine schistosomiasis mansoni. J Immunol 1993: 151: 6994-7004.
47. Springer T A. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994: 76: 301-314.
48. Butcher E C, Picker L J. Lymphocyte homing and homeostasis. Science 1996: 272: 60-66.
49. Talme T, Ivanoff J, Sundqvist K G. Somatostatin is a specific inhibitor of SDF-1alpha-induced T cell infiltration. Clin Exp Immunol 2004: 135: 434-439.
50. Blum A M, Metwali A, Mathew R C, Elliott D, Weinstock J V. Granuloma T lymphocytes in murine schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN- γ secretion. J Immunol 1992: 149: 3621-3626.
51. Hayry P, Raisanen A, Ustinov J, Mennander A, Paavonen T. Somatostatin analog Lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. FASEB J 1993: 7: 1055-1060.
52. Elliott D E, Blum A M, Li J, Metwali A, Weinstock J V. Preprosomatostatin messenger RNA is expressed by inflammatory cells and induced by inflammatory mediators and cytokines. J Immunol 1998: 160: 3997-4003.
53. Matt L H, Kingston T P, Lowe N J. Treatment of severe psoriasis with intravenous somatostatin. J Dermatolog Treat 1989: 181: 81-82.
54. Vaysse N, Lahlou H, Ferjoux G, Susini C. Novel therapeutic targets for somatostatin in inflammatory chronic diseases. Curr Med Chem Anti-inflam Anti-allergy Agents 2005: 4: 91-104.
55. Tallent M, Liapakis G, O'Carrol A M, Lolait S J, Dichter M, Reisine T. Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 1996: 71: 1073-1081.
56. Fagan S P, Azizzadeh A, Moldovan S et.al. Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery 1998: 124: 254-258.
57. Camisa C. Somatostatin therapy. In: Roenigk H H, Maibach H, eds. Psoriasis, 2nd edn. New York: Marcel Dekker Inc., 1991: 829-846.
58. Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis 2002: 5: 231-236.
59. Watson J C, Balster D A, Gebhardt B M et.al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001: 85: 266-272.
60. Albini A, Florio T, Giunciuglio D et.al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 1999: 13: 647-655.